Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 07:05 ET | Source: Research and Markets

Antibody Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 1,486 Deals Signed Since 2019 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...
November 25, 2025 10:01 ET | Source: Research and Markets

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
November 17, 2025 08:00 ET | Source: Artios Pharma

Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib Following encouraging ESMO...
November 17, 2025 05:53 ET | Source: Adcytherix

Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse

Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFOThe ADCX...
October 30, 2025 13:16 ET | Source: Research and Markets

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The...
October 17, 2025 10:30 ET | Source: Artios Pharma

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...
October 17, 2025 10:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...
October 13, 2025 06:30 ET | Source: Artios Pharma

Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage...
October 07, 2025 15:39 ET | Source: MetasTx LLC

NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human

NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.
September 24, 2025 05:00 ET | Source: Artios Pharma

Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)

U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September...